Maarten Lambrecht

Radiation Oncologist

[Jeroen Dekervel @JDekervel]

Cell by cell, we shall unravel the contribution of components in patients with #HCC treated with atezo/bev… https://t.co/e1sP3pTKJR

[Michael B. Keough MD PhD FRCSC @mbkeough]

Tour de force presentation by my former mentor @michelle_monje for the Abhijit Guha Award and Lecture! #SNO2024 #cancerneuroscience

[Scientific Reports @SciReports]

Brain network topology and its cognitive impact in adult glioma survivors, from @LaurienDeRoeck, @mlambr1, @CharlotteSleurs, @treanus, Jeroen Blommaert, and Patrick Dupont
https://t.co/Zy0EUw4VWi

[Laurien De Roeck @LaurienDeRoeck]

📢 our latest research published in @Nature Sci Rep 🧠
https://t.co/fohb41pYub

Our study reveals how structural brain network metrics are altered in glioma survivors and how these changes are linked to cognitive functions.
@mlambr1 @CharlotteSleurs @treanus

[Laurien De Roeck @LaurienDeRoeck]

What a great day at @ESTRO_RT!
An honor to present our results on the role of structural hubs in cognition and the association with RT dose 🧠
@FWOVlaanderen @gminniti2012
#radonc #connectome

[Matthias Guckenberger @Mat_Guc]

Donal Hollywood award winner at #ESTRO24
@piet_ost for the STORM trial
Congrats to @ZilliThomas and all contributors 👏

[OncoAlert @OncoAlert]

New study🚨Out on @NatureComms unveils #HIFI, a groundbreaking spatial proteomic technique🧬, shedding light on diverse responses to radiation therapy☢️ in brain tumors

✅#glioblastoma 🧠undergoes significant spatial reorganization post-treatment, contrasting with brain metastasis.

https://t.co/Zn7pZOs53E

@DrSpencerWatson, @BenoitDuc2, @ZiqiKang2000, @NilsEling, @massara_matteo, @jeanhausser & @Johanna_A_Joyce

#OncoAlertAF
@nataliagandur @acampsmalea @MartaPerachino @heinrich_kat @BiagioRicciutMD @DenizCanGuven1
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Dr_Ivanoncologo @Abdallah81MD @FernandoOnco
@ElisaAgostinett @dr_yakupergun @to_be_elizabeth

[Percy Lee, MD, MBA @PercyLeeMD]

@drdavidpalma @SchneidersFamke Adding to the congratulory comments @drdavidpalma. Your leadership and insight in this trial and space is tremendous.
Looking forward to seeing results from this Herculean effort.

[IJROBP - The Red Journal @IJROBP]

Oh well. Case closed. 😂
@toddscarbrough

[Matthias Guckenberger @Mat_Guc]

#ASTRO2023
Assessment of Precision RT in Early NSCLC and ILD (ASPIRE-ILD) presented by @drdavidpalma
👉 OS at 1-year 78.9%, median OS 25 months
👉 AE event: grade 3 n=4 (10%), grade 4 n=0, grade 5 n=3 (7.7%)
👍 Primary endpoint met, SBRT valid option in overall high-risk pts

[Matthias Guckenberger @Mat_Guc]

#ASTRO2023
High Dose Hyperfractionated Thoracic RT vs. Standard Dose for LS SCLC: Randomized Phase 3 Trial

45Gy in 30 FX vs 54Gy in 30FX
👉 Substantial difference in OS, smaller but significant in PFS
👉 Similar toxicity
❓ Difference in effect size OS vs PFS
❓ Pt selection

[UZ Leuven @UZLeuven]

In UZ Leuven werd voor het eerst een patiënt op het hart bestraald om levensbedreigende ritmestoornissen te verhelpen. Prof. @EctorJoris: "De samenwerking tussen cardiologen en radiotherapeuten biedt onze patiënten een bijkomende behandelingsoptie."
👉 https://t.co/jN8pr9bhD0

[Matthias Guckenberger @Mat_Guc]

Single fraction 8Gy vs SBRT 20Gy for painful bone mets, n=126, mostly non-spine #ESTRO23
Complete pain response at 1 mo primary endpoint
👉 no difference at 1 mo
👉 improved in per protocol analysis after 3mo
👉 no increased toxicity
PATIENT SELECTION IS KEY

[Matthias Guckenberger @Mat_Guc]

OMD requires optimal local & systemic Tx: safe combo of SBRT with novel drugs ?
👉 Consensus about risk mitigation strategies:
❓Same day Tx
❓Interruption or delay of systemic Tx
❓Adaptation of RT dose / fractionation
From @ESTRO_RT & @EORTC #OligoCare
https://t.co/QOhUHL0oca

[EANO @EANOassociation]

Cognitive outcomes after multimodal treatment in adult #glioma patients: A meta-analysis.
https://t.co/C5A6tNnTFF
#btsm @NeuroOnc

[Shankar Siva @_ShankarSiva]

@ErinGillespieMD presents a provocative phase II RCT of prophylactic #radiotherapy to asymptomatic but high risk bone Mets. N=93 Convincing home run, 29% vs 1.6% skeletal related events, with an ⬆️ OS benefit! Remained significant on MVA #ASTRO22 #OncoAlert

[Els Wauters @ewauters]

Happy to share our single cell transcriptomics data on ICI-related pneumonitis in #JITC

[UZ Leuven @UZLeuven]

Goed nieuws in @destandaard vandaag: 6 ziekenhuizen krijgen gespecialiseerde teams voor kanker­patiënten van 16 tot 35 jaar. Met jaarlijks 250 diagnoses investeert @UZLeuven volop in zorg voor jongeren met kanker: https://t.co/rjxMzz67qn @komop_tgkanker
https://t.co/943Lmu20D4

[Oded Rechavi @OdedRechavi]

Struggling to get funding https://t.co/RGLbqVh21z

[Gert De Meerleer @GertMeerleer]

It is gonna be top!